Impact of Diabetes and Hyperlipidemia on Host Defense

糖尿病和高脂血症对宿主防御的影响

• 批准号: 7778257
• 负责人: Hardy Kornfeld
• 金额: $ 39.45万
• 依托单位: UNIV OF MASSACHUSETTS MED SCH WORCESTER
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7778257
• 关键词: 1,2-diacylglycerol; Accounting; Acute; Advanced Glycosylation End Products; Aerosols; Angiotensin II; Animal Model; Apolipoprotein E; Attention; Automobile Driving; Basic Science; Biochemical; Biochemical Pathway; Biological Markers; Blood Pressure; Cell physiology; Cholesterol; Chronic; Clinical; Comorbidity; Complications of Diabetes Mellitus; Data; Dendritic Cells; Diabetes Mellitus; Diabetic mouse; Diet; Diglycerides; Dose; Drug Design; Dyslipidemias; Fatty acid glycerol esters; Growth; Hexosamines; Histopathology; Host Defense; Human; Hyperglycemia; Hyperlipidemia; Immune; Immune system; Immunity; Impairment; Infection; Inflammation; Inflammatory; Insulin Resistance; Insulin-Dependent Diabetes Mellitus; Knock-out; Knockout Mice; Knowledge; Learning; Leukocytes; Link; Lung; Metabolism; Modeling; Morbidity - disease rate; Mus; Mycobacterium tuberculosis; Non-Insulin-Dependent Diabetes Mellitus; Pathway interactions; Pharmaceutical Preparations; Predisposition; Production; Protein Kinase C; Pyridoxamine; Resistance; Role; Serum; Signal Transduction; Streptozocin; Sucrose; T-Lymphocyte; Testing; Time; Tuberculosis; Vascular Diseases; Virulent; adaptive immunity; adiponectin; aminoguanidine; base; benphothiamine; cytokine; diabetic; fighting; high standard; hypercholesterolemia; inhibitor/antagonist; insight; macrophage; mortality; non-diabetic; novel; oxidized low density lipoprotein; polyol; prevent; protective efficacy; research study; response; therapy development; tuberculosis drugs; type I and type II diabetes

Increased susceptibility to infections including tuberculosis (TB) is a major cause of morbidity and mortality in diabetes. Despite its clinical importance, this phenomenon has received little basic research attention. We will investigate TB resistance in mice using models of type 1 and type 2 diabetes. Diabetic and non-diabetic control mice will be challenged by low-dose aerosol infection with Mycobacterium tuberculosis (Mtb). We will characterize TB susceptibility with parameters of survival, bacterial load, and lung leukocyte recruitment. The basis of susceptibility will be evaluated by characterizing cytokine expression and by testing macrophage, dendritic cell, and T cell functions. We will investigate whether advanced glycation end products (AGE), which have been linked to diverse complications of diabetes, are responsible for impaired host defense. We will also evaluate the potential role of other biochemical mechanisms implicated in diabetes complications including polyol pathway flux, hexosamine pathway flux, and over-production of diacylglycerol with activation of protein kinase C. Hyperlipidemia is a common co-morbidity in diabetes that exacerbates diabetic vasculopathy. In preliminary studies we found that hypercholesterolemia also increases TB susceptibility. We will explore similarities and differences in the effects of diabetes and hyperlipidemia on protective immunity, and we will characterize TB susceptibility of mice with combined hyperlipidemia and diabetes. This project will identify specific deficits in protective immunity caused by hyperglycemia and hyperlipidemia, and may provide new insights to critical parameters of host defense against TB. Understanding the mechanisms of susceptibility will inform the development of treatments to reverse this diabetes-related complication. At the same time our model will be used to test the impact on protective immunity of novel treatments for diabetes co-morbidities such as statins, aminoguanidine and pyridoxamine. While our focus is on TB, the new knowledge generated by this project will have broad relevance to other infections associated with diabetes and will further basic understanding of the interplay between immunity and metabolism. This project studies how diabetes weakens the body's ability to fight tuberculosis. Learning more about the harmful effects of diabetes on the immune system will suggest new ways to prevent and treat infections that are a major problem in people with diabetes.

对包括结核病（TB）在内的感染的易感性增加是导致结核病发病率和死亡率的主要原因。 糖尿病尽管其临床重要性，这种现象很少得到基础研究的关注。我们 将使用1型和2型糖尿病模型研究小鼠的结核病耐药性。糖尿病和非糖尿病 对照小鼠将通过结核分枝杆菌（Mtb）的低剂量气溶胶感染进行攻击。我们将 用存活率、细菌载量和肺白细胞募集参数表征TB易感性。的 易感性的基础将通过表征细胞因子表达和通过测试巨噬细胞来评估， 树突细胞和T细胞功能。我们将研究晚期糖基化终末产物（AGE）， 与糖尿病的各种并发症有关，是宿主防御受损的原因。我们 还将评估与糖尿病并发症有关的其他生化机制的潜在作用 包括多元醇途径通量、己糖胺途径通量和二酰基甘油的过度产生 蛋白激酶C高血压是糖尿病常见的合并症， 血管病变在初步研究中，我们发现高胆固醇血症也会增加结核病的易感性。我们 将探讨糖尿病和高脂血症对保护性免疫影响的异同， 我们将研究高脂血症和糖尿病混合型小鼠对结核病的易感性。这个项目 将识别由高血糖症和高脂血症引起的保护性免疫的特定缺陷，并且可以 为主机防御结核病的关键参数提供了新的见解。了解的机制 易感性将为逆转这种糖尿病相关并发症的治疗方法的发展提供信息。在 同时，我们的模型将用于测试糖尿病新疗法对保护性免疫的影响 合并症，如他汀类药物、氨基胍和吡哆胺。虽然我们的重点是结核病， 该项目产生的知识将与其他与糖尿病相关的感染有广泛的相关性 并将进一步了解免疫和新陈代谢之间的相互作用。 该项目研究糖尿病如何削弱身体对抗结核病的能力。更多地了解 糖尿病对免疫系统的有害影响将提出预防和治疗感染的新方法， 是糖尿病患者的主要问题。